August 30, 2006 -- OrthoLogic said that its bone healing drug did not meet endpoints in a Phase IIb study; Canadian biotech AnorMED refused a $355 million bid from Genzyme;PDL BioPharma and Roche dissolved their asthma partnership; Adeza got a recommendation from an FDA advisory committee for itsdrug to prevent preterm birth; Adolor began a Phase I test of ADL5859, a pain drug; Millennium began a Phase I test of an anti-inflammatory compound; an HIV/AIDS vaccine from Targeted Genetics produced a noticeable immune response in a Phase I trial; and the FDA will take an additional three months to review a Wyeth drug for major depressive disorder. The Centient Biotech 200™ climbed 41 points to 3761.84, a gain of 1.10%. More details...
